At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Medication Treatment Study for snOH in Subjects with Primary Autonomic Failure

Clinical Trial Title: 
Phase 3 clinical effect of TD-9855 for treating snOH in subjects with primary autonomic failure.
Clinical Trial Protocol ID: 
18051001
Clinical Trial Investigator Name: 
Katie Kompoliti, MD
Clinical Trial Protocol Description: 

The SEQUOIA Study is a research study looking at a study drug for people with conditions such as Parkinson’s disease (PD) or multiple system atrophy (MSA) who have a drop in blood pressure upon standing. We want to learn how safe the study drug is and whether it can reduce these symptoms. Participation will last about 9 weeks, with 7 study visits.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have been diagnosed with Parkinson’s disease (PD) or multiple system atrophy (MSA),
  • Have symptoms such as dizziness, light-headedness, feeling faint, or feeling like you might black out upon standing.
  • Are 30 years of age or older.
  • Meet additional eligibility criteria.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Parkinson's Disease and Other Movement Disorders
Contact Phone: 
(312) 563-2900 (Press 4/Code: Sequoia 0169)
Contact Name: 
Samantha Ruehl